99mTc-MIBI imaging in the presurgical characterization of thyroid follicular neoplasms: Relationship to multidrug resistance protein expression

Journal of Nuclear Medicine

Volumn 50, Issue 11, 2009, Pages 1785-1793

  Saggiorato, Enrico ^a   Angusti, Tiziana ^a   Rosas, Rosy ^a   Martinese, Morena ^a   Finessi, Monica ^a   Arecco, Federico ^a   Trevisiol, Edoardo ^a   Bergero, Nicoletta ^a   Puligheddu, Barbara ^a   Volante, Marco ^a   Podio, Valerio ^a   Papotti, Mauro ^a   Orlandi, Fabio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Fine needle aspiration biopsy; Multidrug resistance associated protein 1; P glycoprotein; Thyroid 99mtc MIBI scintigraphy; Thyroid follicular neoplasms

Indexed keywords

CALCITONIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; PARATHYROID HORMONE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; DIAGNOSTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ADULT; AGED; APICAL MEMBRANE; ARTICLE; ASPIRATION BIOPSY; CANCER CELL; CANCER CLASSIFICATION; CANCER MORPHOLOGY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTODIAGNOSIS; DIAGNOSTIC IMAGING; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GOITER; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCINTISCANNING; THYROID ADENOMA; THYROID FOLLICULAR NEOPLASM; THYROID NODULE; THYROIDECTOMY; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; TECHNETIUM TC 99M SESTAMIBI; THYROID NEOPLASMS; THYROID NODULE;

EID: 70350738507     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.064980     Document Type: Article

References (44)

1. Schlumberger M, Pacini F. Thyroid Tumors. 2nd ed. Paris, France: Editions Nucléon; 2003:18-24.
2. Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract. 2003;9:128-136.
3. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26:41-44.
4. Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736-744.
5. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28:1336-1340. (Pubitemid 39336372)
6. Kini S. Nodular goiter. In: Thyroid: Guides to Clinical Aspiration Biopsy. New York, NY: Igaku-Shoin; 1987:41-56.
7. Bartolazzi A, Orlandi F, Saggiorato E, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008;9:543-549.
8. Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005;12:305-317.
9. Saggiorato E, Aversa S, Deandreis D, et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest. 2004;27:311-317. (Pubitemid 38744608)
10. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357:1644-1650. (Pubitemid 32568236)
11. Saggiorato E, Cappia S, De Giuli P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:5152-5158. (Pubitemid 33070230)
12. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3015-3020. (Pubitemid 28335081)
13. Carpi A, Naccarato AG, Iervasi G, et al. Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer. 2006;95:204-209. (Pubitemid 44050920)
14. Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr Pathol. 2005;16:295-309.
15. Volante M, Bozzalla-Cassione F, DePompa R, et al. Galectin-3 and HBME- 1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. 2004;445:183-188. (Pubitemid 39215550)
16. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol. 2008;158:375-384.
17. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohisto-chemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005;18:48-57. (Pubitemid 40128094)
18. Hurtado-Lopez LM, Martinez-Duncker C. Negative MIBI thyroid scans exclude differentiated and medullary thyroid cancer in 100% of patients with hypofunctioning thyroid nodules. Eur J Nucl Med Mol Imaging. 2007;34:1701-1703. (Pubitemid 47476931)
19. Hurtado-Lopez LM, Arellano-Montano S, Torres-Acosta EM, et al. Combined use of fine-needle aspiration biopsy, MIBI scans and frozen section biopsy offers the best diagnostic accuracy in the assessment of the hypofunctioning solitary thyroid nodule. Eur J Nucl Med Mol Imaging. 2004;31:1273-1279. (Pubitemid 39222491)
20. Sharma R, Mondal A, Shankar LR, et al. Differentiation of malignant and benign solitary thyroid nodules using 30- and 120-minute tc-99m MIBI scans. Clin Nucl Med. 2004;29:534-537. (Pubitemid 39108856)
21. Sehgal AK, Sathekge MM, Mageza RB, Modiba MC. TC99m MIBI scintigraphy in well-differentiated thyroid carcinoma. Cent Afr J Med. 2001;47:97-102.
22. Erdil TY, Ozker K, Kabasakal L, et al. Correlation of technetium-99m MIBI and thallium-201 retention in solitary cold thyroid nodules with postoperative histopathology. Eur J Nucl Med. 2000;27:713-720. (Pubitemid 30408774)
23. Sathekge MM, Mageza RB, Muthuphei MN, Modiba MC, Clauss RC. Evaluation of thyroid nodules with technetium-99m MIBI and technetium-99m pertechnetate. Head Neck. 2001;23:305-310. (Pubitemid 32234108)
24. Mezosi E, Bajnok L, Gyory F, et al. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the differential diagnosis of cold thyroid nodules. Eur J Nucl Med. 1999;26:798-803. (Pubitemid 29396989)
25. 99mTc- sestaMIBI scan in the diagnostic evaluation of thyroid nodules with oncocytic cytology. Eur J Endocrinol. 2003;149:493-498.
26. Vattimo A, Bertelli P, Cintorino M, Burroni L, Volterrani D, Vella A. Identification of Hurthle cell tumor by single-injection, double-phase scintigraphy with technetium-99m-sestamibi. J Nucl Med. 1995;36:778-782.
27. Chamnanrabiabkij E, Welch A, Jayapaul MK, Perros P. Detection of Hurthle cell carcinoma using sestamibi. Thyroid. 2008;18:575-576. (Pubitemid 351667822)
28. Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging. 2005;32:836-842. (Pubitemid 41125427)
29. Piwnica-Worms DP, Kronauge JF, LeFurgey A, et al. Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magn Reson Imaging. 1994;12:641-652. (Pubitemid 24183127)
30. Chernoff DM, Strichartz GR, Piwnica-Worms D. Membrane potential determination in large unilamellar vesicles with hexakis(2- methoxyisobutylisonitrile)- technetium(I). Biochim Biophys Acta. 1993;1147:262-266. (Pubitemid 23116047)
31. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38:802-832.
32. Altenberg GA. Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Curr Med Chem Anticancer Agents. 2004;4: 53-62.
33. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105-127.
34. Hendrikse NH, Franssen EJ, van der Graaf WT, et al. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer. 1998;77:353-358. (Pubitemid 28044036)
35. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta. 1999;1461:359-376.
36. British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer. In: Perros P, ed. Report of the Thyroid Cancer Guidelines Update Group. 2nd ed. London, U.K.: Royal College of Physicians; 2007:9-10.
37. DeLellis R, Lloyd R, Heitz P, Eng C. Pathology and genetics of tumours of the endocrine organs. In: Kleihues P, Sobin L, eds. World Health Organization Classification of Tumours. Lyon, France: IARC; 2004:49-133.
38. Greenspan BS, Brown ML, Dillehay GL, et al. The Society of Nuclear Medicine Procedure Guideline for Parathyroid Scintigraphy. Version 3.0. Reston, VA: Society of Nuclear Medicine; 2004.
39. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310. (Pubitemid 16134762)
40. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102-132. (Pubitemid 36223282)
41. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
42. Scheffer GL, Kool M, Heijn M, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res. 15 2000;60:5269-5277. (Pubitemid 30739788)
43. Scheper RJ, Bulte JW, Brakkee JG, et al. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer. 1988;42:389-394.
44. Hipfner DR, Gao M, Scheffer G, Scheper RJ, Deeley RG, Cole SP. Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP). Br J Cancer. 1998;78:1134-1140. (Pubitemid 28479139)